[{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","graph1":"Oncology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Private Placement","leadProduct":"Mavorixafor","moa":"CXCR4 ant","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Abingworth","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Abingworth"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","graph1":"Immunology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4","graph1":"Oncology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Private Placement","leadProduct":"Mavorixafor","moa":"CXCR4 ant","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ New Enterprise Associates","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ New Enterprise Associates"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4","graph1":"Hematology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Mavorixafor","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"X4 Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Mavorixafor","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"X4 Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Mavorixafor","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Mavorixafor","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Hercules Capital"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"PANTHERx Rare Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Mavorixafor","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ X4 Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ X4 Pharmaceuticals"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Divestment","leadProduct":"Mavorixafor","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by X4 Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : Xolremdi (mavorixafor) is a selective CXCR4 antagonist, which is being evaluated for the treatment of idiopathic chronic neutropenic disorders who are experiencing recurrent &/​or serious infections.

Brand Name : Xolremdi

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 13, 2024

Lead Product(s) : Mavorixafor

Therapeutic Area : Hematology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : Xolremdi (mavorixafor) is a selective CXCR4 antagonist, which is being evaluated for the treatment of idiopathic chronic neutropenic disorders who are experiencing recurrent &/​or serious infections.

Brand Name : Xolremdi

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 27, 2024

Lead Product(s) : Mavorixafor

Therapeutic Area : Hematology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : Through the divestment, X4 sell its rare pediatric disease priority review voucher for its first approved product, Xolremdi (mavorixafor), a selective CXCR4 receptor antagonist, for WHIM syndrome.

Brand Name : Xolremdi

Molecule Type : Small molecule

Upfront Cash : Undisclosed

May 09, 2024

Lead Product(s) : Mavorixafor

Therapeutic Area : Genetic Disease

Highest Development Status : Approved

Sponsor : Undisclosed

Deal Size : $105.0 million

Deal Type : Divestment

blank

04

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : X4 Pharmaceuticals will distribute Xolremdi (mavorixafor), FDA-approved for patients 12 years and older with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

Brand Name : Xolremdi

Molecule Type : Small molecule

Upfront Cash : Undisclosed

April 29, 2024

Lead Product(s) : Mavorixafor

Therapeutic Area : Genetic Disease

Highest Development Status : Approved

Recipient : PANTHERx Rare Pharmacy

Deal Size : Undisclosed

Deal Type : Partnership

blank

05

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : Xolremdi (mavorixafor) is a selective CXC chemokine receptor 4 (CXCR4) antagonist, which is now approved for the treatment of WHIM syndrome in patients 12 years of age and older.

Brand Name : Xolremdi

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 29, 2024

Lead Product(s) : Mavorixafor

Therapeutic Area : Genetic Disease

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : Mavorixafor is an investigational small-molecule antagonist of the CXCR4 receptor being developed as a once-daily oral therapy for WHIM syndrome and certain chronic neutropenic disorders.

Brand Name : X4P-001

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 31, 2023

Lead Product(s) : Mavorixafor

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

07

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : X4P-001 (mavorixafor) is an investigational small-molecule antagonist of CXCR4 being developed as a once-daily oral therapy to correct the dysfunction resulting from the underlying causes of WHIM.

Brand Name : X4P-001

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 05, 2023

Lead Product(s) : Mavorixafor

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : The financing will be used for the potential commercial launch of X4P-001 (mavorixafor) in individuals with WHIM syndrome and continue to advance mavorixafor for certain chronic neutropenic disorders.

Brand Name : X4P-001

Molecule Type : Small molecule

Upfront Cash : Undisclosed

August 03, 2023

Lead Product(s) : Mavorixafor

Therapeutic Area : Rare Diseases and Disorders

Highest Development Status : Phase III

Sponsor : Hercules Capital

Deal Size : Undisclosed

Deal Type : Financing

blank

09

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : X4 expects to use the proceedings for continued clinical development and commercial readiness of its lead candidate, X4P-001 (mavorixafor), an orally bioavailable CXCR4 antagonist.

Brand Name : X4P-001

Molecule Type : Small molecule

Upfront Cash : Undisclosed

May 16, 2023

Lead Product(s) : Mavorixafor

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Piper Sandler

Deal Size : $65.0 million

Deal Type : Private Placement

blank

10

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : X4P-001 (mavorixafor) is an investigational small-molecule antagonist of CXCR4 being developed as a once-daily oral therapy to correct the dysfunction resulting from the underlying causes of WHIM.

Brand Name : X4P-001

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 16, 2023

Lead Product(s) : Mavorixafor

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank